Novacap to acquire PCI Synthesis.
M2 PHARMA-June 22, 2018-Novacap to acquire PCI Synthesis
(C)2018 M2 COMMUNICATIONS
Canada-based pharmaceutical synthesis company, Novacap, has agreed to acquire Boston-based PCI Synthesis, a pharmaceutical contract development and manufacturing organisation (CDMO), it was reported yesterday.
Financial details of the deal were not revealed. The transaction is subject to customary merger control approval. BlackArch Partners served as the exclusive financial advisor to PCI Synthesis.
Combined, the two firms will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap's global position in pharmaceutical synthesis with 12 cGMP sites, two main R&D centres and its comprehensive range of services and technologies dedicated to clinical development and commercial manufacturing.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 22, 2018|
|Previous Article:||PharmaEngine announces encouraging topline results from global pivotal trial of PEP503 in soft tissue sarcoma.|
|Next Article:||Novo Nordisk reports success in two Semaglutide phase 3a trials.|